CP-102

About Contera Pharma

Contera Pharma is a private, clinical-stage biotech company based in Hørsholm, Denmark, pioneering RNA-targeting therapeutics for neurological disorders. Its core asset is a proprietary discovery platform that integrates data for a precision medicine approach to identify and validate novel targets. The company has advanced its lead asset, CP-012 for Parkinson's disease, to Phase 1b with positive topline results, and is pursuing strategic partnerships, notably a 2025 research collaboration with Lundbeck, to expand its pipeline and accelerate development.

About Cage Pharma (2)

Cage Pharma is a private, preclinical-stage biotech founded in 2018, targeting the oncology market with a novel approach to disrupting cancer metabolism. The company's core strategy centers on CP-102, a compound designed to specifically inhibit tumor glycolysis, a process many cancers rely on for growth. As a preclinical entity, the company is likely funded by venture capital or grants and is preparing for its first-in-human trials. Success hinges on demonstrating clinical proof-of-concept for its metabolic inhibition approach, which could offer a new mechanism of action in oncology.

Therapeutic Areas

Other Canavan disease Drugs